atai Life Sciences ist Teilnehmer der im April stattfindenden Investorenkonferenz
April 20, 2022 12:04 ET
|
atai Life Sciences
NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) („atai“), ein biopharmazeutisches Unternehmen für den klinischen Bereich, das sich der Aufgabe verschrieben hat,...
atai Life Sciences to Participate in Upcoming April Investor Conference
April 19, 2022 12:26 ET
|
atai Life Sciences
NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,...
atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and Highlights Strategic Focus Areas of its Innovative Mental Health Platform
March 30, 2022 06:59 ET
|
atai Life Sciences
– Highlights included positive Phase 2b data with COMP360 from a ground-breaking treatment resistant depression (TRD) trial, highly encouraging Phase 2a proof-of-mechanism data with RL-007 in...
atai Life Sciences to Host Conference Call and Webcast to Discuss Results for the Fourth Quarter and Full Year 2021 and Corporate Update
March 23, 2022 06:59 ET
|
atai Life Sciences
NEW YORK and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health...
atai Life Sciences to Participate in Upcoming March Investor Conferences
March 21, 2022 13:08 ET
|
atai Life Sciences
NEW YORK, March 21, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,...
atai Impact spendet an die Multidisciplinary Association for Psychedelic Studies (MAPS), um deren Pionierarbeit in der psychedelischen Medizin zu unterstützen
February 16, 2022 17:47 ET
|
atai Life Sciences
- Führende gemeinnützige und kommerzielle Organisationen der psychedelischen Wissenschaft teilen die Vision von der Heilung psychischer Erkrankungen - Die Spende kommt von atai Impact, dem...
atai Impact Donates to the Multidisciplinary Association for Psychedelic Studies (MAPS) to Support Pioneering Work in Psychedelic Medicine
February 16, 2022 06:59 ET
|
atai Life Sciences
- Leading non-profit and commercial organizations in psychedelic science united in visions to heal mental health conditions - Donation is from atai Impact, the philanthropic arm of mental health...
atai Life Sciences to Participate in Upcoming February Investor Conference
February 15, 2022 06:59 ET
|
atai Life Sciences
NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,...
atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments
January 27, 2022 06:59 ET
|
atai Life Sciences
Invyxis will add proven medicinal chemistry and comprehensive biological evaluation capabilities to grow atai’s portfolio of new chemical entities (NCEs) Early focus will be on designing unique,...
atai Life Sciences gibt FDA-Freigabe eines neuen Prüfpräparats (Investigational New Drug, IND) für das PCN-101 R-Ketamin-Programm bekannt
January 13, 2022 13:02 ET
|
atai Life Sciences
• Ermöglicht die Ausweitung der klinischen Entwicklung von PCN-101 auf die USA • atai plant den Start einer klinischen Studie zur Arzneimittelwechselwirkung (drug-drug interaction, DDI) Anfang 2022,...